Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Academic Article Article uri icon

Overview

MeSH Major

  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Hypertrophy, Left Ventricular

abstract

  • Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.

publication date

  • March 23, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(02)08090-X

PubMed ID

  • 11937179

Additional Document Info

start page

  • 1004

end page

  • 10

volume

  • 359

number

  • 9311